Article info

Download PDFPDF
Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis

Authors

  • Xintong Li Center for Drug Safety and Effectiveness, Johns Hopkins University, Baltimore, Maryland, USA Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Kathleen M Andersen Center for Drug Safety and Effectiveness, Johns Hopkins University, Baltimore, Maryland, USA Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Hsien-Yen Chang Center for Drug Safety and Effectiveness, Johns Hopkins University, Baltimore, Maryland, USA Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA PubMed articlesGoogle scholar articles
  • Jeffrey R Curtis Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA PubMed articlesGoogle scholar articles
  • G Caleb Alexander Center for Drug Safety and Effectiveness, Johns Hopkins University, Baltimore, Maryland, USA Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr G Caleb Alexander, Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA; galexan9{at}jhmi.edu
View Full Text

Citation

Li X, Andersen KM, Chang H, et al
Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis

Publication history

  • Received July 29, 2019
  • Revised September 13, 2019
  • Accepted September 18, 2019
  • First published October 31, 2019.
Online issue publication 
January 27, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.